highly significantp < 0.001
In severe frailty, 54.5% (45/82) experienced a decrease in polypharmacy, while 45.5% (37/82) remained unchanged, and no increase was observed, with a highly significant p -value ( p < 0.001) [ 96 ]. 3.8.
In severe frailty, 54.5% (45/82) experienced a decrease in polypharmacy, while 45.5% (37/82) remained unchanged, and no increase was observed, with a highly significant p -value ( p < 0.001) [ 96 ]. 3.8.
[ 58 ], showed a clear trend of increasing PIM use from non-frail to frail categories using different versions of the Beers Criteria and STOPP-J.